Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications, as well as for cardiovascular, musculo-skeletal, respiratory, and nervous system; alimentary tract and metabolism; antiinfectives for systemic use; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. Its products include Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor, and Efficib/Tesavel. Almirall, S.A. has collaboration and partnership agreements with Tyris Therapeutics, BIOMAP, the University of Dundee, Kaken Pharmaceutical Co Ltd., Ichnos Sciences Inc., the University Carlos III Madrid and MEDINA Foundation, 23andMe, Inc., HitGen Ltd., WuXi Biologics, Eli Lilly and Company, and Athenex, Inc. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
P/E ratio for Almirall, S.A. (ALM.MC)
P/E ratio as of 2023: -43.16
According to Almirall, S.A.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -43.16. At the end of 2022 the company had a P/E ratio of 381.70.
P/E ratio history for Almirall, S.A. from 2005 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -43.16 |
| 2022 | 381.70 |
| 2021 | -49.48 |
| 2020 | 25.75 |
| 2019 | 24.07 |
| 2018 | 32.34 |
| 2017 | -4.85 |
| 2016 | 33.82 |
| 2015 | 24.44 |
| 2014 | 5.30 |
| 2013 | -60.74 |
| 2012 | 16.91 |
| 2011 | 10.48 |
| 2010 | 9.55 |
| 2009 | 10.04 |
| 2008 | 6.56 |
| 2007 | 19.01 |
| 2006 | 16.56 |
| 2005 | 20.71 |